Introduction
Besides their role in hemostasis, platelets release antimicrobial substances and are able to recruit cells of the immune system to the site of injury by secreting proinflammatory factors [1, 2] . Platelets interact with a wide spectrum of pathogens, including viruses, bacteria, protozoa and fungi [3] [4] [5] [6] . Gram-negative and Gram-positive bacteria and their secreted products activate platelets, strain-specifically either directly or through plasma proteins acting as bridging molecules [7] [8] [9] , by complex mechanisms involving the platelet Fc-receptor FccRIIA [10] [11] [12] , glycoprotein (GP) aIIbb3, GPIba, complement receptors (e.g. gC1q-R) and Toll-like receptors (e.g. TLR-2 and TLR-4) [7, 13, 14] . Upon activation, platelets release antimicrobial substances such as reactive oxygen species (ROS), antimicrobial peptides, defensins, kinocidins and proteases [15] [16] [17] [18] . In addition, platelets also release inorganic polyphosphates (polyP), which are potent procoagulant and proinflammatory molecules [19, 20] and the chemokine CXCL4 or platelet factor 4 (PF4) [21] [22] [23] .
The positively charged tetrameric chemokine PF4 is released from the a-granules of activated platelets. When PF4 binds to strongly charged polyanions such as heparin, it changes its conformation, exposing neoepitopes [24, 25] . This triggers formation of antiplatelet factor 4/ heparin (anti-PF4/P) IgG antibodies [25] [26] [27] . Previously it has been shown that PF4 binds to lipid A, the basic structure of lipopolysaccharide (LPS), on Gram-negative bacteria [28, 29] and to not yet identified structures on Gram-positive bacteria. This allows binding of anti-PF4/ P IgG antibodies, which in turn promotes bacterial phagocytosis by granulocytes [29] .
In this study, we show that platelets kill PF4-coated Escherichia coli (E. coli) after recognizing anti-PF4/P IgG antibodies, which requires FccRIIA, functional GP aIIbb3 and an intact platelet cytoskeleton.
Methods

Bacterial strain preparation and killing assays in suspension
Escherichia coli K-12 wild type (WT) strain BW30270and the lipopolysaccharide (LPS) mutants KPM53 (DwaaC) and KPM121 (DwaaA) were grown in an overnight culture of LB medium at 37°C with a constant stirring rate of 115 rpm. The main culture was then inoculated (OD 600 of 0.08) and further incubated at 37°C and 115 rpm until the exponential phase (OD 600 of 0.8). Bacteria were harvested by centrifugation at 3000 9 g for 5 min and the bacterial pellet was resuspended in ice-cold phosphate buffered saline (PBS) and kept on an ice-cold block until further use. Platelets were isolated as described [30] . All suspension co-culture experiments were performed with washed platelets in the presence of modified Tyrode's buffer supplemented with albumin, glucose, MgCl 2 and CaCl 2 . For killing assays in suspension culture, unstimulated platelets and E. coli were mixed at a ratio of 25 : 1 and incubated at 37°C for 60 min on a horizontal shaker in a sterile microwell plate. The plate was then floated on a 37°C water bath for another 60 min before adding a 2% v/v Saponin solution to lyse platelets. The bacteria were separated from platelet debris by centrifugation at 3000 g for 5 min and the bacterial suspension was serially diluted (up to 1:1000 in triplicates), plated on LB agar plates, and incubated overnight at 37°C. Colonyforming units per mL (CFU mL ) were determined by manual counting for each plate. For preparing the E. coli for killing assays, 20 lg mL À1 PF4 was incubated with the bacteria for 30 min at 4°C and the unbound excess was washed by centrifugation at 3000 9 g for 5 min. Anti-PF4/ P IgG purified from Heparin-induced thrombocytopenia (HIT) patients was used at 0.375 lg mL À1 , 1.5 lg mL À1 and 7.5 lg mL À1 to assess the concentration-dependent killing of bacteria by platelets. Platelet activation was measured by P-selectin expression on platelets upon their interaction with E. coli K-12 WT strain BW30270 and LPS mutants KPM53 (DwaaC) and KPM121 (DwaaA) in the presence of PF4 and anti-PF4/P IgG in suspension culture.
For inhibition experiments, platelets were pretreated for 30 min at 37°C with the receptor blockers anti-FccRIIA mAb (clone IV.3, purified from hybridoma) at 4 lg mL
À1
and abciximab at 10 lg mL À1 , and cytoskeletal inhibitors cytochalasin D at 25 lM and blebbistatin at 10 lM. Prior to adding bacterial suspensions, pretreated platelets were rinsed by centrifugation at 750 9 g for 5 min twice. PF4 (up to 50 lg mL À1 ) added alone did not inhibit the growth and/ or kill E. coli ( Figure S1 ).
Preparation of and functionalization of micropatterned arrays with live E. coli
Electron beam lithography (EBL) was used to prepare micropatterned arrays on glass coverslips as previously described [31, 32] . Briefly, coverslips were sputter coated with chromium followed by gold to create a conductive layer and functionalized with PEG-thiol (5 mg mL À1 in deionized water for 24 h). To create patterned microarrays, 5% v/v bovine serum albumin (BSA) in deionized water was spun for 40 s at 2000 rpm on a self-assembled monolayer of PEG-thiol. EBL was performed at optimal electron beam dosage of 80 lC cm À2 to produce high-fidelity BSA micropatterns in a Zeiss Supra 40 VP scanning electron microscope (SEM) equipped with an ELPHY Quantum EBL system (Raith GmbH, Dortmund, Germany). Live bacteria were immobilized on micropatterns using 1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) and N-hydroxysuccinimide (NHS) chemistry [33] . A total of 8000 single bacteria were analyzed for each experimental condition from three biological replicate experiments using platelets isolated from three healthy donors. Image analysis was performed using image processing software Leica LAS AF and Imaris Version 7.6.5 (Bitplane, Switzerland) and percent (%) live/dead ratio was calculated.
Determination of a-granule polarity index (PI)
Platelets (labelled with Cell Mask Green) on bacteria micropatterns were fixed in 2% v/v paraformaldehyde/ PBS, pH 7.5, for 30 min. Paraformaldehyde was quenched with 30 mM glycine/PBS, pH 7.5, for 5 min, followed by permeabilization for 10 min with 0.1% Triton-X100 and 0.5% BSA. P-selectin was immunofluorescently labelled and bacteria were stained by DAPI (4 0 ,6-diamidino-2-phenylindole). Confocal fluorescent Z-stacks (30 images at an interval of 350 nm) were acquired from 10 micropatterns each from three different donors. To compensate for blurring of the fluorescence signal due to diffraction artifacts, image stacks were deconvoluted on ImageJ using the plugin DeconvolutionLab2 [34] . The extent of a-granule polarization towards the platelet:bacteria interface was quantified on Imaris Version 7.6.5 (Bitplane, Switzerland) and was adopted from a method described previously [35] . The a-granule polarity index (PI) was defined as the distance along the z-axis between the position of a-granules and bacteria on the micropatterns (mean distance of all detected a-granules denoted by a) divided by distance along the z-axis between the middle of the platelet (dashed line) and the platelet:bacteria interface plane (denoted by b) ( Figure S7 ). A PI of < 0.75 was chosen as a conclusive indication of a a-granule polarization event for localization of a-granules towards the platelet:bacteria interface.
Statistical analysis
All statistical analyses were performed with GraphPad Prism version 5.03 software. Data are presented as mean AE SD, except where indicated. Statistical significance was calculated by the two-tailed Student's t-test and one-way ANOVA followed by Dunnett's multiple comparison test and significance was set at P < 0.05.
Ethics
The use of human sera with HIT antibodies and of human platelets obtained from healthy volunteers was approved by the ethics board at the University of Medicine Greifswald.
Results
PF4 and anti-PF4/P IgG-coated E. coli are killed by human platelets in suspension co-culture Escherichia coli K-12 wild-type (WT) strain BW30270 and the isogenic LPS mutant strains KPM53 (DwaaC) and KPM121 (DwaaA) have progressive truncations in their LPS chain [28] and show enhanced PF4 binding and opsonization by anti-PF4/P IgG in comparison to the WT K-12 strain BW30270 ( Figure S2 A, B and C). At a bacteria to platelet ratio of 1 : 25 and in the presence of PF4 and anti-PF4/P IgG, platelets were able to kill E. coli mutants KPM53 (DwaaC) (Fig. 1B) and KPM121 (DwaaA) (Fig. 1C) . In contrast, this mechanism was less effective against E. coli K-12 WT strain BW30270 (Fig. 1A) , which showed only minor PF4 binding. The antibacterial effect of platelets in the presence of PF4 was dependent on the concentration of anti-PF4/P IgG: KPM121 (DwaaA) at 0.375 lg mL À1 IgG (CFU mL À1 of 2.18 9 10 4 AE 0.22), at 1.5 lg mL À1 IgG (CFU mL À1 of 1.7 9 10 4 AE 0.46) and at 7.5 lg mL À1 IgG (CFU mL Killing of E. coli by platelets in co-culture in the presence of PF4 and anti-PF4/P IgG requires FccRIIA, integrin aIIbb3 and a functional platelet cytoskeleton. Analysis of colony forming units (CFU) from co-culture experiments wherein (A) E. coli K-12 WT strain BW30270 and the LPS mutants (B) KPM53 (DwaaC) and (C) KPM121 (DwaaA) were incubated with platelets at a ratio of 1 : 25, showing killing of E. coli opsonized with PF4 and anti-PF4/P IgG in the presence of platelets. In some experiments blockers for FccRIIA (mAb IV.3), integrin aIIbb3 (abciximab) and cytoskeletal inhibitors (blebbistatin and cytochalasin D) were used for pretreatment of platelets. Data represent mean AE standard deviation [SD] from n = 3 donors. One-way ANOVA followed by Dunn's multiple comparison test. **P < 0.001; ***P < 0.001 and ns-not significant [Color figure can be viewed at wileyonlinelibrary.com] of 0.71 9 10 4 AE 0.19) (Fig. 1C ) compared with the controls incubated only with 7.5 lg mL À1 anti-PF4/P IgG (CFU mL À1 3.4 9 10 4 AE 0.38). Similarly, in the presence of 7.5 lg mL À1 anti-PF4/P IgG and PF4, platelets were able to kill KPM53 (DwaaC) (CFU mL À1 1.13 9 10 4 AE 0.25) (Fig. 1B) in comparison to the control (absence of PF4 and presence of anti-PF4/P IgG: CFU mL À1 3.15 9 10 4 AE 0.66). The E. coli WT K-12 strain BW30270 was less effectively killed by platelets in the presence of PF4 and anti-PF4/P IgG (Fig. 1A) . These results showed a clear dependence of killing of Gram-negative E. coli based on their capacity to bind PF4 and, more importantly, on the concentration of anti-PF4/P IgG. Platelets co-incubated with E. coli mutants KPM53 (DwaaC) (Fig. 1B) and KPM121 (DwaaA) coated with PF4 and opsonized by anti-PF4/P IgG were found to be more activated than E. coli WT K-12 strain BW30270, as shown by an increase in surface P-selectin by flow cytometry ( Figure S3) .
Pretreatment of platelets with FccRIIA blocking mAb IV.3 abrogated the antibacterial effect of platelets in the presence of PF4 and anti-PF4/P IgG (at 7.5 lg mL À1 for KPM53 (DwaaC) CFU 2.8 9 10 4 AE 0.44 and for KPM121 (DwaaA) 2.5 9 10 4 AE 0.45). Similar results were obtained by pretreatment of platelets with the integrin aIIbb3 blocking antibody abciximab and cytoskeletal inhibitors cytochalasin D and blebbistatin (Fig. 1B,C) . These results clearly show that PF4 together with anti-PF4/P IgG in the presence of platelets mediates an antibacterial defense. In addition, functional platelet integrin aIIbb3 and coordination of cytoskeletal elements are essential for this biological function of platelets.
FccRIIA-dependent human platelet adhesion and spreading on E. coli is enhanced by binding of anti-PF4/P IgG antibodies to PF4-coated bacteria
To visualize and quantify the interaction of single human platelets with bacteria, leading to bacterial killing, we developed a micropatterned array with viable E. coli immobilized on a glass coverslip. Bacteria were immobilized on BSA micropatterns of 10-lm diameter separated from each other by a non-adhesive polyethylene glycol (PEG) surface (Fig. 2A) . E. coli K-12 WT strain BW30270 and the LPS mutants KPM53 (DwaaC) and KPM121 (DwaaA) maintained their viability upon immobilization on micropatterned arrays, as shown by staining with SYTO9 Live Cell dye (Fig. 2B) .
Immunofluorescence quantification of anti-PF4/P IgG binding to E. coli on micropatterns showed significant differences between all three types of E. coli (wild-type E. coli K-12 WT strain BW30270 > LPS mutant KPM53 (DwaaC) > LPS mutant KPM121 (DwaaA); Fig. 2B,C) , in line with our previous observations [28] . Consistently, more platelets adhered and showed extensive spreading on KPM53 (DwaaC) (coverage 46.7% AE 7.25) and KPM121 (DwaaA) (coverage 60.6% AE 10.4) compared with the WT K-12 strain BW30270 (coverage 15.1% AE 4.65) in the presence of PF4 and anti-PF4/P IgG (Fig. 3A, B) . Binding of platelets to E. coli was significantly inhibited by pretreating platelets with FccRIIA blocking mAb IV.3 to 12.90% AE 6.1 (P < 0.0001) on KPM53 (DwaaC) and 13.60% AE 9.1 (P < 0.0001)) on KPM121 (DwaaA) (Fig. 3A, B ).
PF4 and anti-PF4/P IgG-coated E. coli are killed by human platelets on micropatterns
We further performed live/dead staining of E. coli KPM121 (DwaaA) to visualize and quantify whether platelets are able to kill bacteria on micropatterns after incubation with platelets for 2 h (Fig. 4) . In comparison to the control (10.4% AE 2.3; platelets only), we observed a higher percentage of dead bacteria on micropatterns (39.2% AE 14.9; P = 0.0149) in the presence of PF4 and anti-PF4/P IgG. Bacterial killing primarily occurred at sites where platelets co-localized with PF4 and anti-PF4/P opsonized bacteria ( Figure S4 ). Bacterial killing was significantly diminished upon blocking of FccRIIA by pretreatment of platelets with mAb IV.3 (8.8% AE 3.4; P = 0.0131), abciximab (14% AE 5.1; P = 0.0150), cytochalasin D (10.6% AE 5.32, P = 0.0141) and blebbistatin (12.6% AE 6.58; P = 0.056). Live confocal imaging of platelets on PF4 and anti-PF4/P IgG opsonized bacteria on micropatterns showed high Ca 2+ mobilization, indicating platelet activation ( Figure S5 ). Furthermore, we also observed, filopodia-and lamellipodia-like extensions accompanied by dynamic membrane ruffling during platelet spreading, with which platelets were able to displace bacteria immobilized on micropatterns (Movie S1). This phenomenon was inhibited by cytochalasin D or blebbistatin (Movies S2 and S3).
Confocal fluorescence microscopy imaging of P-selectin expression upon platelet activation with anti-PF4/P opsonized E. coli KPM121 (DwaaA) on micropatterns showed a significant increase in P-selectin levels, which was inhibited by mAb IV.3, abciximab, cytochalasin D and blebbistatin (Fig. 5A,B) . The 3D iso-surface rendering of confocal Z-stacks of platelets on E. coli KPM121 (DwaaA) micropatterns opsonized with PF4 and anti-PF4/P IgG revealed increased deposition of a-granuleassociated P-selectin towards the bacteria on the micropatterns in comparison with those platelets pretreated with cytochalasin D and blebbistatin (Fig. 5C, D) , as measured by calculating the a-granule polarity index outlined in the Methods section. Taken together, these results indicate that platelet activation and bacterial killing in the presence of PF4 and anti-PF4/P IgG depends on FccRIIA-mediated interactions. In addition, these results point towards a synergistic role of the platelet cytoskeleton and integrin aIIbb3 in FccRIIA-mediated platelet activation.
Discussion
This study shows that human platelets have direct FccRIIA-mediated antimicrobial effects and further indicates that they also bridge innate and adaptive immunity via the chemokine PF4. PF4 binds to a large variety of bacteria and undergoes a conformational change exposing neoepitopes [10, 28, 29] . Anti-PF4/P antibodies recognize these neoepitopes on PF4, which enables the host to fight many different bacterial species by using a single antibody specificity (anti-PF4/P antibodies), being ready in place (or produced within 5-7 days) to bind to PF4/polyanion complexes on the bacterial surface even if the immune system of the host has not seen the bacterial species before.
Interactions of platelets with Gram-positive and Gram-negative bacteria involve highly complex dynamic molecular recognition events coordinated through multiple transmembrane receptors on platelets [4, 8, 36] . We recapitulated the key findings of these experiments with micropatterns of living bacteria and co-cultivation of platelets with these bacteria in the presence of PF4 and anti-PF4/P antibodies. This not only confirms that platelets strongly interact with immune complexes [37] , but is also indicative that the platelet FccRIIA may mediate directed movement of platelets. It has been well established that the platelet FccRIIA is dynamically linked to the integrin aIIbb3 on the platelet membrane. This link is involved in outside-in signaling of both receptors as well as inside-out activation of aIIbb3 [38, 39, 40] . Furthermore, both signal transduction processes are associated with platelet cytoskeletal reorganization [39, 41] . In a recent study it has been elegantly demonstrated under in vitro conditions that platelets recognize aggregated IgG on immobilized surfaces via FccRIIa, leading to platelet activation and agranule secretion [38] . Secreted a-granule-derived fibrinogen further supports aIIbb3-mediated platelet interaction and spreading, resulting in signal amplification. It was also observed that blocking of aIIbb3 with antagonists and by using aIIbb3-deficient platelets, results in complete abrogation of platelet spreading and thrombus formation.
We believe a similar mechanism underlies the effects observed in our experiments, where anti-PF4/P antibodies bound to PF4 complexes substitute for the aggregated IgG. Furthermore, pretreatment of platelets with actin cytoskeleton-destabilizing agents is known to decrease the kinetics and inhibit secretion of a-granule contents by possibly restricting their membrane fusion events [42] . Therefore, we assume that blockade of aIIbb3 or inhibition of the cytoskeleton dynamics by cytochalasin D and blebbistatin inhibits site-directed alpha granule release. Furthermore, we also observed formation of microaggregates of platelets around opsonized bacteria within 15 min of co-incubation in suspension culture (Figure S6) . This observation suggests that by forming microaggregates, platelets can achieve a local higher concentration of antibacterial substances around the bacteria, thus facilitating inhibition of bacterial growth and ultimately resulting in their killing.
Our study also provides a new model of how platelets interfere with bacteria. Internalization of IgG-coated targets [43, 44] by platelets has been established [45] . However, it is debated whether phagocytosis of bacteria (i.e. Staphylococcus aureus [46] ) is really a major mechanism for bacterial host defense [47, 48] . Bactericidal substances are stored in platelet a-granules [49] . However, it is unlikely that phagocytosed bacteria are transported within the platelet into the a-granules [48] . If such a mechanism takes place it would make much more sense that platelets form a globular shape instead of spreading thin over a large area with the a-granules concentrated in the immediacy of the granulomere [50] . In addition, using extracellular matrix protein (fibrinogen and collagen) based protein micropatterns, Sakurai et al. have shown that platelet agranule secretion is modulated by the underlying matrix and platelets were capable of secreting their own matrix proteins in order to spread, with actin polymerization and integrin aIIbb3 playing significant roles in these processes [51] . Based on these observations, we propose here an alternative mechanism wherein instead of phagocytosis, platelets cover bacteria by widely extending their + a n t i -P F 4 / P I g G + P l a t e l e t s + P F 4 + a n t i -P F 4 / P I g G + P l a t e l e t s + P F 4 + a n t i -P Comparison of a-granule polarity index (PI) from Z-stacks of platelets immunofluorescently labelled for intra-platelet P-selectin in adhesion experiments on PF4 and anti-PF4/P IgG opsonized E. coli KPM121(DwaaA) shows significantly higher a-granule polarization towards the platelet:bacteria interface. Data represent mean AE standard deviation [SD] from 10 single platelets from three different donors (n = 30 platelets) for each experimental condition. One-way ANOVA followed by Dunn's multiple comparison test and **P < 0.05. [Color figure can be viewed at wileyonlinelibrary.com] membranes and then actively contracting them, thereby centralizing bacteria until they are very close to the granulomere of platelets, where the substances with antibacterial potency are stored (Fig. 5 C, D and Movie S1). When a threshold concentration of platelet activating signals is reached due to platelet interaction with the opsonized bacteria, the activated platelets release their a-granules preferentially at the site of the bacteria, thereby locally reaching high concentrations of antibacterial substances. This phenomenon is similar to the pore-forming perforin released from the granules at the immunological synapse potentiated by cytotoxic T lymphocytes [52] . Moreover, coverage of bacteria by the platelet membrane prevents dilution of the antibacterial substances by the surrounding fluids.
The proposed platelet-mediated bacterial defense mechanism via PF4 and FccRIIA is not the only mechanism, as platelets are known to inhibit Staphylococcus aureus growth in vitro independently of FccRIIA, which, however, requires higher platelet to bacteria ratios [17, 18] . Consistent with the findings of other groups, we observed inhibition of E. coli growth at concentrations of >500 platelets per bacterium (data not shown) in co-culture experiments. However, in the presence of PF4 and anti-PF4/P antibodies, the ratio of % 25 platelets per bacterium was sufficient to kill E. coli. In every experiment, we controlled for other effects by using the E. coli K-12 WT strain BW30270, and the mutants KPM53 (DwaaC) and KPM121 (DwaaA), which did not cause platelet activation alone. Also in the presence of control IgG and by blocking the FccRIIA of platelets, no platelet activation occurred. This makes it unlikely that other mediators apart from PF4 and anti-PF4/P IgG were responsible for platelet activation by anti-PF4/P IgG-opsonized bacteria. The observation that E. coli K-12 WT strain BW30270 was not effectively killed by platelets is consistent with our previous studies, in which we showed that PF4 has only a height of 5 nm, and an IgG has a length of about 10 nm. LPS reaches a length of up to 25 nm, therefore sterically hiding the Fc part of the IgG for the platelet Fc receptor, as the complex of PF4/lipid A with a bound anti-PF4/P IgG cannot reach out of the LPS cover. However, we have also shown that polyphosphates can overcome the inhibitory effect of longer LPS chains by forming larger PF4/polyphosphate complexes [24] .
Our in vitro studies do not allow for quantifying the in vivo relevance of FccRIIA and PF4-mediated bacterial host defense by platelets. Humans with a low platelet count often also have an impaired bone marrow (e.g. due to chemotherapy) and the increased risk of bacterial infection is primarily attributed to the low granulocyte count. Individuals with a low platelet count due to immune thrombocytopenia have an enhanced platelet turnover, which does not exclude that platelets are still able to defend microorganisms before they are removed from the circulation. Interestingly, however, patients with a-granule deficiency are described as suffering from increased bacterial infections [53] . Most animal models are difficult to apply, as mice do not express FccRIIA. Even using transgenic mice expressing human FccRIIA does not allow testing for the effect of human anti-PF4/P antibodies. A further limitation is that we did not have access to human platelets lacking a-granule proteins including PF4 due to a genetic defect (e.g. Gray platelet syndrome) and can therefore not differentiate between the effects of externally supplemented PF4 in the experiments and endogenous platelet-derived PF4.
Taken together, we provide a new mechanism of human bacterial host defense in which platelets with their chemokine PF4 and FccRIIA are engaged in the crosstalk between the innate and adaptive immune systems. PF4 binds to a wide variety of bacteria. Anti-PF4/polyanion antibodies opsonize bacteria coated with PF4, which are then sensed by platelets via their Fc receptor. The opsonized bacteria are covered by the spreading platelet, and probably exposed to a high concentration of antimicrobial substances released from activated platelets in a directed manner towards the bacteria. This mechanism efficiently inhibits bacterial growth. S1 . Titration of PF4 without addition of anti-PF4/P IgG shows that PF4 alone has no effect on bacterial viability. Fig. S2 . Detection of PF4 binding to E. coli WT K12-BW30270, and LPS mutants KPM53 (DwaaC) and KPM121 (DwaaA). Fig. S3 . P-selectin expression on platelets. Fig. S4 . Confocal fluorescence images of colocalization of platelets (blue) with dead E. coli KPM 121 (DwaaA) (red) on micropatterns. Fig. S5 . Imaging of calcium mobilization in platelets. Fig. S6 . Platelets form microaggregates around anti-PF4/ P opsonized E. coli KPM121 (DwaaA). Fig. S7 . Schematics for calculation of a-granule polarity index (PI) from confocal Z-stacks of platelet adhesion experiments on bacteria immobilized micropatterns. Movie S1. Platelet interaction with PF4 and anti-PF4/P IgG opsonized bacteria on micropatterns. Movie S2. Effect of cytichalasin D on platelet interaction with PF4 and anti-PF4/P IgG opsonized bacteria on micropatterns. Movie S3. Effect of blebbistatin on platelet interaction with PF4 and anti-PF4/P IgG opsonized bacteria on micropatterns.
